Proposed Local Coverage Determination (LCD) Released for Comment - Glucose Monitors

Posted October 6, 2022

The Centers for Medicare and Medicaid Services (CMS) assigned to the Durable Medical Equipment Medicare Administrative Contractors (DME MACs) the task of developing LCDs for Durable Medical Equipment, Prostheses, Orthoses, and Supplies (DMEPOS). The DME MACs are proposing one LCD as described below:

Glucose Monitors (DL33822) - Proposing modifications to coverage criteria for continuous glucose monitors (CGMs)

Stakeholders may read the details of the proposed LCD posted on the Medicare Coverage Database by referencing the LCD ID number in the search field. The entire proposed LCD should be reviewed prior to the submission of written comments.

We are soliciting comments on the proposed LCD from stakeholders (including, but not limited to, clinicians, manufacturers, suppliers, and other parties who care for Medicare beneficiaries). You should be very specific in your comments, and if possible, offer suggestions that may address your concerns. You should provide an evidence-based rationale for your comments and attach any full-text references from the published clinical literature (for example, peer-reviewed journals, clinical society guidelines, etc.) that were not included in the bibliography of the proposed LCD. We encourage a written response regardless of your agreement or disagreement with the proposed LCD.

In your comments, please be sure to disclose all conflicts of interest you have with any manufacturer(s) or supplier(s) of glucose monitors.

All comments will be collected at a single point of contact for the proposed LCD. Do not include any protected health information (PHI) or personally identifiable information (PII). Please submit your comments electronically to the DME MACs at the email address below no later than Saturday, November 19, 2022 at 5 p.m. ET.

Glucose Monitors (DL33822): GLULCDCOMMENTS@cgsadmin.com

Suppliers and clinicians are cautioned not to make any changes based upon information contained in a proposed LCD. The content of a proposed LCD may be revised based upon the written comments received during the comment period. When all written comments have been reviewed, revisions will be considered.

*IMPORTANT: The DME MACs will host a virtual open meeting to further solicit input from stakeholders for the proposed LCD. The virtual meeting will take place on November 15, 2022. For details regarding participation in the virtual open meeting, refer to the open meeting announcement article posted at Open Meeting Announcement - Glucose Monitors Proposed Local Coverage Determination (LCD)

Refer to each DME MAC website for additional information, including access to the proposed LCD.

Thank you for your participation in our policy development process.

Smitha M. Ballyamanda, MD, CAQSM
Medical Director, DME MAC Jurisdiction A
Noridian Healthcare Solutions, LLC

Sunil V. Lalla, MD, FACS, CPC
Medical Director, DME MAC Jurisdiction B
CGS Administrators, LLC

Robert D. Hoover, Jr., MD, MPH, FACP
Medical Director, DME MAC Jurisdiction C
CGS Administrators, LLC

Angela S. Jenny, DO
Medical Director, DME MAC, Jurisdiction D
Noridian Healthcare Solutions, LLC

 

Last Updated Oct 05 , 2022